Table 2.
Predictive value of PD-L1 score concerning treatment outcome.
| Disease control (complete/partial response, stable disease) | Treatment non-responders (progress) | p | |
|---|---|---|---|
|
All CPI treatments (n = 78) PD-L1 | |||
| Positive | 13 | 14 | 0.447 |
| Negative | 20 | 31 | |
|
All anti-PD-1 treatments (nivolumab, pembrolizumab, ipilimumab + nivolumab) PD-L1 | |||
| Positive | 8 | 8 | 1.0 |
| Negative | 15 | 15 | |
|
Ipilimumab PD-L1 | |||
| Positive | 5 | 6 | 0.215 |
| Negative | 5 | 16 | |
|
Nivolumab PD-L1 | |||
| Positive | 0 | 1 | 1.0 |
| Negative | 5 | 5 | |
|
Pembrolizumab PD-L1 | |||
| Positive | 7 | 5 | 0.654 |
| Negative | 9 | 9 | |
|
Ipilimumab + Nivolumab PD-L1 | |||
| Positive | 1 | 2 | 1.0 |
| Negative | 1 | 1 | |